Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16927797 | 0.95 | CHRNB2 (0.42) | NAMPTMMP2MMP13RAB9ASLC6A5 | |
| SCHEMBL648783 | 0.93 | SMN1; SMN2 (0.46) | NAMPTMMP2MMP13RAB9ATPSAB1 | |
| SCHEMBL4458748 | 0.92 | NAMPT (0.44) | NAMPTRAB9ATPSAB1MEN1KMT2A | |
| SCHEMBL648628 | 0.91 | CHRNB2 (0.41) | NAMPTMMP2MMP13RAB9ASLC6A5 | |
| SCHEMBL648627 | 0.91 | CHRNB2 (0.41) | NAMPTMMP2MMP13RAB9ASLC6A5 | |
| SCHEMBL4403519 | 0.91 | NAMPT (0.46) | NAMPTRAB9ATPSAB1MEN1KMT2A | |
| SCHEMBL16927791 | 0.88 | SMN1; SMN2 (0.45) | NAMPTMMP2MMP13RAB9ATPSAB1 | |
| SCHEMBL648168 | 0.86 | SLC6A5 (0.58) | SLC6A5SLC6A4 | |
| SCHEMBL648854 | 0.83 | PRKAA2 (0.44) | NAMPTSLC6A5SLC6A4GAAPRKAA2 | |
| SCHEMBL4402680 | 0.82 | CHRNB2 (0.44) | NAMPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231600-B1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-8119809-B2 | AMPK-activating heterocycloalkyloxy(hetero)aryl carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | claimed |
| EP-2231600-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | claimed |
| WO-2009065131-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | claimed |
| CN-111212883-B | Volatile material emitting composition | 住友精化株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-107250456-B | Solid compositions comprising quaternary ammonium compounds and polysaccharides, processes and uses thereof | 罗地亚经营管理公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-111212883-A | Volatile material emitting composition | 住友精化株式会社 | 2020-05-29 | — | — | CN | disclosed |
| CN-110475862-A | Detergent composition | CONOPCO INC | 2019-11-19 | — | — | CN | disclosed |
| CN-109844083-A | whitening composition | 荷兰联合利华有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-108699490-A | Lightening compositions | 荷兰联合利华有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108603139-A | Whitening composition | 荷兰联合利华有限公司 | 2018-09-28 | — | — | CN | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2111214-B1 | MICROCAPSULES | GIVAUDAN SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100009893-A1 | Microcapsules | GIVAUDAN SA (CH) | 2010-01-14 | — | — | US | disclosed |
| EP-2111214-A1 | MICROCAPSULES | Givaudan SA (CH) | 2009-10-28 | — | — | EP | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2008098387-A1 | MICROCAPSULES | GIVAUDAN SA (CH) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | NAMPT 291/4885MMP2 2956/4885MMP13 3119/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | NAMPT 172/4885MMP2 4740/4885MMP13 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.